Skip to main content

Etidronate Beneficial for Arterial Calcification Due to CD73 Deficiency

Medically reviewed by Carmen Pope, BPharm. Last updated on April 9, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, April 9, 2024 -- For patients with arterial calcification due to deficiency of CD73 (ACDC), etidronate may slow progression of vascular calcification in the lower extremities, according to a study published online April 3 in Vascular Medicine.

Elisa A. Ferrante, Ph.D., from the National Heart, Lung, and Blood Institute at the National Institutes of Health in Bethesda, Maryland, and colleagues examined the safety and effectiveness of etidronate in attenuating the progression of lower-extremity arterial calcification and vascular blood flow. Seven adults with ACDC were enrolled into a single-arm pilot study; participants received etidronate for 14 days every three months and were followed biannually for three years.

The researchers found that the progression of further vascular calcification in the lower extremities as measured by computed tomography was slowed by etidronate treatment, but treatment had no effect on reversing vascular and/or periarticular joint calcifications.

"Despite the small sample size, these results potentially suggest that etidronate, which is still available outside of the United States, could be considered for patients with progressive vascular calcification due to ACDC, particularly given the total lack of any other treatment options for this disease," the authors write. "In addition, the knowledge gained with respect to the natural history, pathology, and clinical presentation of ACDC has been invaluable and will inform the development of novel therapies and larger clinical trials for this and other calcifying vascular diseases."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

COVID-19 Hospitalization Equivalent to Coronary Artery Disease for MACE Risk

WEDNESDAY, Oct. 9, 2024 -- Hospitalization for COVID-19 represents a coronary artery disease risk equivalent, contributing to an increased risk for major adverse cardiovascular...

Aromatase Inhibitors Not Linked to CAC in Postoperative Breast Cancer Patients

TUESDAY, Sept. 17, 2024 -- For postoperative patients with breast cancer, the duration of aromatase inhibitor (AI) treatment is not associated with the risk for coronary artery...

Lower Potassium Threshold After CABG Safe for A-Fib Prevention

WEDNESDAY, Sept. 4, 2024 -- Potassium supplementation at a threshold of <3.6 mEq/L is noninferior to the current 4.5-mEq/L threshold to prevent atrial fibrillation after...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.